Author

Sophie Roche

Institution: Centre Jean Bernard

Observed institution: Centre Jean Bernard

ORCID: 0009-0008-1138-3998

Observed ORCID: 0009-0008-1138-3998

OpenAlex ID: A5132558876

ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

2026 · Guillaume Beinse, Valerie Taly, et al. · Clinical Cancer Research · 2

ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial

2026 · Félix Blanc-Durand, Catherine Genestie, et al. · Clinical Cancer Research · 2

Supplementary Table S1 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

2026 · Guillaume Beinse, Valerie Taly, et al.

Supplementary Figure S3 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

2026 · Guillaume Beinse, Valerie Taly, et al.

Supplementary Figure S2 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

2026 · Guillaume Beinse, Valerie Taly, et al.

Supplementary Figure S8 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

2026 · Guillaume Beinse, Valerie Taly, et al.

Supplementary Figure S6 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

2026 · Guillaume Beinse, Valerie Taly, et al.

Supplementary Figure S7 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

2026 · Guillaume Beinse, Valerie Taly, et al.

Supplementary Figure S1 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

2026 · Guillaume Beinse, Valerie Taly, et al.

Supplementary Figure S5 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

2026 · Guillaume Beinse, Valerie Taly, et al.

Supplementary Figure S4 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

2026 · Guillaume Beinse, Valerie Taly, et al.

Data from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

2026 · Guillaume Beinse, Valerie Taly, et al.

Supplementary Figure S9 from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

2026 · Guillaume Beinse, Valerie Taly, et al.

Data from ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial

2026 · Félix Blanc-Durand, Catherine Genestie, et al.

Supplementary Table S1 from ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial

2026 · Félix Blanc-Durand, Catherine Genestie, et al.

Works count: 15

Citation count: 4

H-index: 2

I10-index: